Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label sonelokimab study in moderate-to-severe palmoplantar pustulosis
2024-513305-32-00Phase 2Completed
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Oct 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonelokimab in Palmoplantar Pustular Psoriasis (PPPP), sponsored by MoonLake Immunotherapeutics. Primary endpoint: Percent change from baseline in PPPASI score at Week 16. Started Oct 2024; status: completed.
02
Drugs
sonelokimab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on 2024-513305-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513305-32-00.